作为刺激剂使用障碍的药物候选者,CM699的临床前资料
Takato Hiranita1, Weimin C Hong2, Abhisheak Sharma3,4,5
1Department of Pharmacology, Joe R. and Teresa Lozano Long School of Medicine, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, Texas 78229, United States.
一种新型化合物,CM699,通过双重多巴胺转运器和西格玛受体抑制,显示出治疗兴奋剂使用障碍的前景. 这种双重作用有效地阻止了在滥用潜力较低的临床前模型中自我管理可卡因.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 成 药物 药物 药物 药物
背景情况:
- 目前用于兴奋剂使用障碍 (SUD) 的治疗方法缺乏经过证明的疗效.
- 单独的西格玛受体 (σR) 抗剂不会阻断刺激剂的强化.
- 结合 σR 反对和多巴胺载体 (DAT) 阻塞可能会减弱兴奋剂自给的作用.
研究的目的:
- 为了研究双重DAT/σR抑制剂CM699在治疗兴奋剂使用障碍方面的疗效.
- 评估CM699的药理特征,体内效应和滥用潜力.
主要方法:
- 合成和CM699在DAT和sR亲和关系的体外表征.
- 评估CM699对多巴胺吸收和sR多元化的影响.
- 在老鼠体内进行的研究评估了CM699对可卡因诱导的多巴胺水平的影响,自我管理以及其自身的滥用潜力.
主要成果:
- CM699对DAT和sRs具有很高的亲和力,抑制了多巴胺的外生吸收.
- CM699有效地阻断了可卡因的自我注射,并在体内抑制了可卡因的刺激作用.
- CM699显示出极小的滥用潜力,并阻断了可卡因引起的DAT.的形状变化.
结论:
- 双DAT/σR抑制是SUD药物开发的新的临床前方法.
- CM699的机制涉及调节DAT形状,提供了一个新的治疗策略.
- 这些发现为开发用于兴奋剂使用障碍的双重作用药物提供了概念证明.
更多相关视频
10:02Event Related Potentials ERPs and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder ADHD
Published on: March 12, 2020
08:20MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
Published on: August 11, 2015
相关概念视频
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Preclinical Development: Overview
Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
Adrenergic Agonists: Mixed-Action Agents
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
